Dawson James analyst Jason Kolbert maintained a Buy rating on Cytosorbents (CTSO – Research Report) on November 22 and set a price target of $16.00. The company's shares closed last Tuesday at $4.03. According to TipRanks.com, Kolbert has 0 stars on 0-5 stars ranking scale with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Currently, the analyst consensus on Cytosorbents is a Strong Buy with an average price target of $12.75.
https://www.tipranks.com/news/blurbs/dawson-james-remains-a-buy-on-cytosorbents-ctso?utm_source=advfn.com&utm_medium=referral